A Study of LY3039478 in Healthy Participants

Phase 1

Completed

Interventions: Drug: Placebo
Drug: LY3039478 Formulated Capsule (Test, Formulation 3)
Drug: LY3039478 Capsule Formulation (Formulation 3)
Drug: LY3039478 Drug-in Capsule (Reference, Formulation 1)

Brief Summary: The main purpose of this study is to investigate the safety of the study drug known as LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part A has three periods. Either LY3039478 or placebo will be given once by mouth in each period. Part B has two periods. Participants will receive both formulations of LY3039478, by mouth, over the course of the study. Both parts of the study will also explore how much LY3039478 gets into the bloodstream and how long it takes the body to get rid of it. Information about any side effects will also be collected. Participants may only enroll in one part. The study will last at least 33 days, not including screening. Screening must be performed up to 30 days before enrollment.

Part B was added by protocol amendment approved in April, 2016.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Known allergies to LY3039478, related compounds or any components of the formulation

Arm && Interventions

Group	Intervention	Description
Part A: Placebo	Placebo	Single oral dose of placebo administered in one of three study periods
Part B: LY3039478 Formulated Capsule (Test, Formulation 3)	LY3039478 Formulated Capsule (Test, Formulation 3)	Single oral 50 mg dose of formulated capsule (test, formulation 3) LY3039478 administered in one of two study periods
Part A: LY3039478 Capsule Formulation (Formulation 3)	LY3039478 Capsule Formulation (Formulation 3)	Escalating single oral dose of 25 milligram (mg), 50 mg, and 75 mg capsule formulation (formulation 3) LY3039478 administered in two of three study periods
Part B: LY3039478 Drug-In Capsule (Reference, Formulation 1)	LY3039478 Drug-in Capsule (Reference, Formulation 1)	Single oral 50 mg dose of drug-in capsule (reference, formulation 1) LY3039478 administered in one of two study periods

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics (PK): Mean Time-Matched Difference in Placebo-Adjusted QTcF Interval With Time Matched Concentrations Between LY3039478 Capsule Formulation (Formulation 3) Part A	Predose, 0.5, 1, 2, 3, 4, 6, 8,12, 24, 36, 48 Hours Postdose	PK: mean time-matched difference in QTcF interval with time-matched concentrations between LY3039478 capsule formulation (formulation 3) compared to placebo. Analyses of QTcF was assessed by the mean change in QTcF as a function of plasma drug concentration. Triplicate measures at each time point was averaged prior to analysis. The primary analysis was based on the time-matched placebo-adjusted QTcF (ΔQTcF) for each time point, which was calculated by subtracting each participant's time-matched placebo QTcF from their QTcF results after receiving LY3039478. The relationship between plasma concentrations of LY3039478 and ΔQTcF was evaluated using a linear mixed-effects modeling approach. The response variable was ΔQTcF, and concentrations was fitted as a fixed effect with participants as a random effect. The regression slope was presented with the unit in "milliseconds per nanogram per milliliter" abbreviated as "ms/ng/mL".

Secondary Outcome Measures

Name	Time	Method
PK: AUC(0-∞) of the 2 Formulations of LY3039478 Part B	Predose, 0.5, 1, 2, 3, 4, 6, 8,12, 24, 36, 48 Hours Postdose	PK is the AUC(0-∞) of the 2 formulations of LY3039478 in part B.
PK: Cmax of LY3039478 Capsule Formulation (Formulation 3) Part A	Predose, 0.5, 1, 2, 3, 4, 6, 8,12, 24, 36, 48 Hours Postdose	PK is Cmax of LY3039478 capsule formulation (formulation 3) in part A.
PK: Cmax of the 2 Formulations of LY3039478 Part B	Predose, 0.5, 1, 2, 3, 4, 6, 8,12, 24, 36, 48 Hours Postdose	PK is the Cmax of the 2 formulations of LY3039478 in part B
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3039478 Capsule Formulation (Formulation 3) Part A	Predose, 0.5, 1, 2, 3, 4, 6, 8,12, 24, 36, 48 Hours Postdose	PK is the area under the concentration versus time curve from zero to infinity (AUC\[0-∞\]) of LY3039478 capsule formulation (formulation 3) in part A.